B. Brown

发表

Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment

J. Hokanson, S. Deeb, J. Brunzell, 2001 .

Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease.

S. Deeb, J. Brunzell, W. Yang, 1996, Journal of lipid research.

Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.

J. Hokanson, S. Deeb, J. Brunzell, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.M200439-JLR200

A. Lichtenstein, E. Schaefer, B. Brown, 2003, Journal of Lipid Research.

Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease

S. Deeb, J. Brunzell, A. Zambon, 2006, Journal of internal medicine.

Effect of hepatic lipase on LDL in normal men and those with coronary artery disease.

J. Hokanson, M. Austin, J. Brunzell, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400304-JLR200

P. Duchateau, S. Deeb, M. Malloy, 2005, Journal of Lipid Research.

Should both HDL-cholesterol and LDL-C be targets for lipid therapy? A review of current evidence

M. Cheung, B. Brown, Xuelei Zhao, 2012 .

Familial combined hyperlipidemia and abnormal lipoprotein lipase.

J. Brunzell, B. Brown, S. P. Babirak, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.

J. Hokanson, J. Brunzell, A. Zambon, 1999, Circulation.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

J. Tomassini, S. Fazio, J. Guyton, 2008, Journal of the American College of Cardiology.

Types of Change in Coronary Stenosis Severity and Their Relative Importance in Overall Progression and Regression of Coronary Disease

J. Albers, X. Zhao, L. Hillger, 1994, Annals of the New York Academy of Sciences.

Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment

J. Hokanson, S. Deeb, J. Brunzell, 2000, Circulation.

Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid‐lowering therapy

J. Hokanson, B. G. Brown, A. Motulsky, 2006, Journal of internal medicine.

Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography

J. Frohlich, M. Dobiášová, M. Cheung, 2011, Journal of Lipid Research.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

E. Bolson, B. G. Brown, A. Chait, 2001, The New England journal of medicine.

Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL

B. G. Brown, A. Chait, J. Albers, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.

B. G. Brown, X. Zhao, B. Brown, 2008, The American journal of cardiology.

Antioxidant vitamins and lipid therapy: end of a long romance?

B. G. Brown, A. Chait, X. Zhao, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Effects of Prolonged Intensive Lipid-Lowering Therapy on the Characteristics of Carotid Atherosclerotic Plaques In Vivo by MRI: A Case-Control Study

K R Maravilla, C. Yuan, T. Hatsukami, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Niaspan® in the management of dyslipidaemia: the evidence

B. G. Brown, B. Brown, 2006 .

Association of apolipoprotein B gene variants with plasma apoB and low density lipoprotein (LDL) cholesterol levels

E. Wijsman, B. G. Brown, A. Motulsky, 1992, Human Genetics.

Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS).

X. Zhao, B. Neradilek, B. Brown, 2014, Journal of Clinical Lipidology.

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials

B. G. Brown, X. Zhao, Xue-Qiao Zhao, 2006, Current opinion in lipidology.

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

B. G. Brown, A. Chait, J. Frohlich, 2004, The American journal of cardiology.